Basilea Secures USD 268 Million Agreement with BARDA to Develop Novel Antifungal and Antibacterial Treatments

(IN BRIEF) Basilea Pharmaceutica has entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of novel antifungal and antibacterial treatments. The agreement provides an initial USD 29 million, with the potential … Read the full press release →